Radiopharmaceuticals Market

Pages:
351
View Count:
28475
Delivery Formats:
PDF PPT Excel
Radiopharmaceuticals Market

Lowest Price Guaranteed

download button Download Free Sample

sales@rootsanalysis.com

buynow button Buy Now

+44 (122) 391 1091

Radiopharmaceuticals Market (2nd Edition) by Type of Radioisotope (Technetium-99m, Lutetium-177, Fluorine-18 and Others), Type of Emitter (Gamma Emitters, Beta Emitters, and Others), Purpose of Radiopharmaceutical (Diagnostics and Therapeutics), Type of Diagnostic Radiopharmaceutical (PET Imaging Agents and SPECT Imaging Agents), Type of Production Method (Nuclear Reactors, Accelerators / Cyclotrons, and Others), Therapeutic Area, End-user and Geographical Regions - Trends and Forecast 2026-2040

Table of Contents

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations on the Industry

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Overview of Radiopharmaceuticals

6.3. Mechanism of Action of Radiopharmaceuticals

6.4. Types of Radiopharmaceuticals

6.5. Applications of Radiopharmaceuticals

6.6. Advantages of Radiopharmaceuticals

6.7. Challenges in Radiopharmaceutical Development and Clinical Use

6.8. Recent Trends in the Radiopharmaceuticals Domain

+ 7. REGULATORY LANDSCAPE
+ 8. MARKET LANDSCAPE: APPROVED RADIOPHARMACEUTICAL THERAPY PROGRAMS

8.1. Methodology and Key Parameters

8.2. Approved Radiopharmaceuticals: Therapy Programs

8.2.1. Analysis by Format of Radiopharmaceutical

8.2.2. Analysis by Type of Radioisotope

8.2.3. Analysis by Type of Emitter

8.2.4. Analysis by Purpose of Radiopharmaceutical

8.2.5. Analysis by Therapeutic Area

8.2.6. Analysis by Target Indication

8.2.7. Analysis by Route of Administration

8.2.8. Analysis by Dosing Frequency

8.3. Approved Radiopharmaceuticals: Developer Landscape

8.3.1. Analysis by Year of Establishment

8.3.2. Analysis by Company Size

8.3.3. Analysis by Location of Headquarters

8.3.4. Most Active Players: Analysis by Number of Approved Radiopharmaceuticals

+ 9. MARKET LANDSCAPE: CLINICAL AND PRECLINICAL RADIOPHARMACEUTICAL THERAPY PROGRAMS

9.1. Methodology and Key Parameters

9.2. Clinical and Preclinical Radiopharmaceuticals: List of Therapy Programs

9.2.1. Analysis by Stage of Development

9.2.2. Analysis by Type of Radioisotope

9.2.3. Analysis by Type of Emitter

9.2.4. Analysis by Purpose of Radiopharmaceutical

9.2.5. Analysis by Type of Therapy

9.2.6. Analysis by Route of Administration

9.2.7. Analysis by Target Indication

9.2.8. Analysis by Therapeutic Area

9.2.9. Analysis by Target Patient Population

9.3. Clinical and Preclinical Radiopharmaceuticals: Developer Landscape

9.3.1. Analysis by Year of Establishment

9.3.2. Analysis by Company Size

9.3.3. Analysis by Location of Headquarters

9.3.4. Most Active Players: Analysis by Number of Clinical and Preclinical Radiopharmaceuticals

+ 10. COMPANY PROFILES

10.1. 3BP Pharmaceuticals

10.1.1. Company Overview

10.1.2. Management Team

10.1.3. Radiopharmaceuticals Pipeline

10.1.4. Recent Initiatives

10.2. Curium

10.3. ITM Radiopharma

10.4. Jubilant Radiopharma

10.5. Lantheus

10.6. Yantai LNC Biotechnology

10.7. Norroy Biosciences

10.8. Sinotau Pharmaceutical

10.9. Telix Pharmaceuticals

+ 11. PARTNERSHIPS AND COLLABORATIONS

11.1. Methodology and Key Parameters

11.2. Partnership Models

11.3. Radiopharmaceuticals: Partnerships and Collaborations

11.3.1. Analysis by Year of Partnership

11.3.2. Analysis by Type of Partnership

11.3.3. Analysis by Year and Type of Partnership

11.3.4. Analysis by Type of Radioisotope

11.3.5. Analysis by Type of Emission

11.3.6. Analysis by Type of Molecule

11.3.7. Analysis by Therapeutic Area

11.3.8. Analysis by Purpose of Radiopharmaceutical

11.3.9. Analysis by Type of Partner

11.3.10. Most Active Players: Analysis by Number of Partnerships

11.3.11. Analysis by Local and International Agreements

11.3.12. Analysis by Intercontinental and Intracontinental Agreements

+ 12. CLINICAL TRIAL ANALYSIS

12.1. Methodology and Key Parameters

12.2. Radiopharmaceuticals: Clinical Trial Analysis

12.2.1. Analysis by Trial Registration Year

12.2.2. Analysis by Trial Status

12.2.3. Analysis by Trial Registration Year and Trial Status

12.2.4. Analysis of Patient Enrolled by Trial Registration Year

12.2.5. Analysis by Trial Phase

12.2.6. Analysis of Patient Enrolled by Trial Phase

12.2.7. Analysis by Type of Sponsor / Collaborator

12.2.8. Analysis by Study Design

12.2.9. Analysis by Patient Gender

12.2.10. Analysis by Target Patient Population

12.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials

12.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials

12.2.13. Geographical Distribution: Analysis by Number of Trials and Patients Enrolled

12.2.14. Analysis by Trial Status and Geography

12.2.15. Analysis of Patients Enrolled by Trial Status and Geography

+ 13. MEGA TREND ANALYSIS

13.1. Megatrends Analysis: An Overview of the Emerging Trends

13.1.1. Expansion of Targeted Alpha Therapies (TATs)

13.1.2. Integration of AI in Radiopharmaceuticals Development

13.1.3. Advent of Theranostics

13.1.4. Expanding Applications across Diverse Indications

13.1.5. Innovations in Supply Chain and Infrastructure Advancement

13.1.6. Rise in Strategic Collaborations and Investments

+ 14. MARKET IMPACT ANALYSIS

14.1. Chapter Overview

14.2. Market Drivers

14.3. Market Restraints

14.4. Market Opportunities

14.5. Market Challenges

14.6. Conclusion

+ 15. GLOBAL RADIOPHARMACEUTICALS MARKET

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

15.3.1. Scenario Analysis

15.3.1.1. Conservative Scenario

15.3.1.2. Optimistic Scenario

15.4. Key Market Segmentations

+ 16. RADIOPHARMACEUTICALS MARKET, BY TYPE OF RADIOISOTOPE

16.1. Radiopharmaceuticals Market: Distribution by Type of Radioisotope

16.1.1. Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

16.1.2. Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

16.1.3. Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

16.1.4. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 17. RADIOPHARMACEUTICALS MARKET, BY TYPE OF EMITTER

17.1. Radiopharmaceuticals Market: Distribution by Type of Emitter

17.1.1. Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

17.1.2. Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

17.1.3. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 18. RADIOPHARMACEUTICALS MARKET, BY PURPOSE OF RADIOPHARMACEUTICALS

18.1. Radiopharmaceuticals Market: Distribution by Purpose of Radiopharmaceuticals

18.1.1. Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

18.1.2. Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 19. RADIOPHARMACEUTICALS MARKET, BY TYPE OF DIAGNOSTIC RADIOPHARMACEUTICALS

19.1. Radiopharmaceuticals Market: Distribution by Type of Diagnostic Radiopharmaceuticals

19.1.1. Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

19.1.2. Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 20. RADIOPHARMACEUTICALS MARKET, BY TYPE OF PRODUCTION METHOD

20.1. Radiopharmaceuticals Market: Distribution by Type of Production Method

20.1.1. Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

20.1.2. Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

20.1.3. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 21. RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC AREA

21.1. Radiopharmaceuticals Market: Distribution by Therapeutic Area

21.1.1. Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

21.1.2. Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

21.1.3. Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

21.1.4. Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

21.1.5. Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

21.1.6. Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 22. RADIOPHARMACEUTICALS MARKET, BY END-USER

22.1. Radiopharmaceuticals Market: Distribution by End-user

22.1.1. Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

22.1.2. Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

22.1.3. Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 23. RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHICAL REGIONS

23.1. Radiopharmaceuticals Market: Distribution by Geographical Regions

23.2. Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.2.1. Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.2.2. Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3. Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.1. Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.2. Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.3. Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.4. Radiopharmaceuticals Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.5. Radiopharmaceuticals Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.3.6. Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4. Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.1. Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.2. Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.3. Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.4. Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.5. Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.4.6. Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.5. Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.5.1. Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.5.2. Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.6. Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.6.1. Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.6.2. Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

23.6.3. Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

24.1 Radiopharmaceuticals Market in North America: Distribution by Type of Radioisotope

24.1.1. Radiopharmaceuticals Market in North America for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.1.2. Radiopharmaceuticals Market in North America for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.1.3. Radiopharmaceuticals Market in North America for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.1.4. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.2. Radiopharmaceuticals Market in North America: Distribution by Type of Emitter

24.2.1. Radiopharmaceuticals Market in North America for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.2.2. Radiopharmaceuticals Market in North America for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.2.3. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.3. Radiopharmaceuticals Market in North America: Distribution by Purpose of Radiopharmaceutical

24.3.1. Radiopharmaceuticals Market in North America for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.3.2. Radiopharmaceuticals Market in North America for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.4. Radiopharmaceuticals Market in North America: Distribution by Type of Diagnostic Radiopharmaceutical

24.4.1. Radiopharmaceuticals Market in North America for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.4.2. Radiopharmaceuticals Market in North America for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.5. Radiopharmaceuticals Market in North America: Distribution by Type of Production Method

24.5.1. Radiopharmaceuticals Market in North America for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.5.2. Radiopharmaceuticals Market in North America for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.5.3. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6. Radiopharmaceuticals Market in North America: Distribution by Therapeutic Area

24.6.1. Radiopharmaceuticals Market in North America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6.2. Radiopharmaceuticals Market in North America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6.3. Radiopharmaceuticals Market in North America for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6.4. Radiopharmaceuticals Market in North America for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6.5. Radiopharmaceuticals Market in North America for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.6.6. Radiopharmaceuticals Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.7. Radiopharmaceuticals Market in North America: Distribution by End-user

24.7.1. Radiopharmaceuticals Market in North America for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.7.2. Radiopharmaceuticals Market in North America for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24.7.3. Radiopharmaceuticals Market in North America for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 25. MARKET OPPORTUNITY ANALYSIS: EUROPE

25.1 Radiopharmaceuticals Market in Europe: Distribution by Type of Radioisotope

25.1.1. Radiopharmaceuticals Market in Europe for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.1.2. Radiopharmaceuticals Market in Europe for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.1.3. Radiopharmaceuticals Market in Europe for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.1.4. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.2. Radiopharmaceuticals Market in Europe: Distribution by Type of Emitter

25.2.1. Radiopharmaceuticals Market in Europe for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.2.2. Radiopharmaceuticals Market in Europe for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.2.3. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.3. Radiopharmaceuticals Market in Europe: Distribution by Purpose of Radiopharmaceutical

25.3.1. Radiopharmaceuticals Market in Europe for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.3.2. Radiopharmaceuticals Market in Europe for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.4. Radiopharmaceuticals Market in Europe: Distribution by Type of Diagnostic Radiopharmaceutical

25.4.1. Radiopharmaceuticals Market in Europe for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.4.2. Radiopharmaceuticals Market in Europe for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.5. Radiopharmaceuticals Market in Europe: Distribution by Type of Production Method

25.5.1. Radiopharmaceuticals Market in Europe for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.5.2. Radiopharmaceuticals Market in Europe for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.5.3. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6. Radiopharmaceuticals Market in Europe: Distribution by Therapeutic Area

25.6.1. Radiopharmaceuticals Market in Europe for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6.2. Radiopharmaceuticals Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6.3. Radiopharmaceuticals Market in Europe for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6.4. Radiopharmaceuticals Market in Europe for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6.5. Radiopharmaceuticals Market in Europe for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.6.6. Radiopharmaceuticals Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.7. Radiopharmaceuticals Market in Europe: Distribution by End User

25.7.1. Radiopharmaceuticals Market in Europe for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.7.2. Radiopharmaceuticals Market in Europe for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

25.7.3. Radiopharmaceuticals Market in Europe for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

26.1 Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Radioisotope

26.1.1. Radiopharmaceuticals Market in Asia-Pacific for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.1.2. Radiopharmaceuticals Market in Asia-Pacific for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.1.3. Radiopharmaceuticals Market in Asia-Pacific for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.1.4. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.2. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Emitter

26.2.1. Radiopharmaceuticals Market in Asia-Pacific for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.2.2. Radiopharmaceuticals Market in Asia-Pacific for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.2.3. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.3. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Purpose of Radiopharmaceutical

26.3.1. Radiopharmaceuticals Market in Asia-Pacific for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.3.2. Radiopharmaceuticals Market in Asia-Pacific for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.4. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Diagnostic Radiopharmaceutical

26.4.1. Radiopharmaceuticals Market in Asia-Pacific for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.4.2. Radiopharmaceuticals Market in Asia-Pacific for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.5. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Type of Production Method

26.5.1. Radiopharmaceuticals Market in Asia-Pacific for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.5.2. Radiopharmaceuticals Market in Asia-Pacific for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.5.3. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6. Radiopharmaceuticals Market in Asia-Pacific: Distribution by Therapeutic Area

26.6.1. Radiopharmaceuticals Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6.2. Radiopharmaceuticals Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6.3. Radiopharmaceuticals Market in Asia-Pacific for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6.4. Radiopharmaceuticals Market in Asia-Pacific for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6.5. Radiopharmaceuticals Market in Asia-Pacific for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.6.6. Radiopharmaceuticals Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.7. Radiopharmaceuticals Market in Asia-Pacific: Distribution by End-user

26.7.1. Radiopharmaceuticals Market in Asia-Pacific for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.7.2. Radiopharmaceuticals Market in Asia-Pacific for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

26.7.3. Radiopharmaceuticals Market in Asia-Pacific for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 27. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

27.1 Radiopharmaceuticals Market in Latin America: Distribution by Type of Radioisotope

27.1.1. Radiopharmaceuticals Market in Latin America for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.1.2. Radiopharmaceuticals Market in Latin America for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.1.3. Radiopharmaceuticals Market in Latin America for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.1.4. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.2. Radiopharmaceuticals Market in Latin America: Distribution by Type of Emitter

27.2.1. Radiopharmaceuticals Market in Latin America for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.2.2. Radiopharmaceuticals Market in Latin America for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.2.3. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.3. Radiopharmaceuticals Market in Latin America: Distribution by Purpose of Radiopharmaceutical

27.3.1. Radiopharmaceuticals Market in Latin America for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.3.2. Radiopharmaceuticals Market in Latin America for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.4. Radiopharmaceuticals Market in Latin America: Distribution by Type of Diagnostic Radiopharmaceutical

27.4.1. Radiopharmaceuticals Market in Latin America for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.4.2. Radiopharmaceuticals Market in Latin America for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.5. Radiopharmaceuticals Market in Latin America: Distribution by Type of Production Method

27.5.1. Radiopharmaceuticals Market in Latin America for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.5.2. Radiopharmaceuticals Market in Latin America for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.5.3. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6. Radiopharmaceuticals Market in Latin America: Distribution by Therapeutic Area

27.6.1. Radiopharmaceuticals Market in Latin America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6.2. Radiopharmaceuticals Market in Latin America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6.3. Radiopharmaceuticals Market in Latin America for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6.4. Radiopharmaceuticals Market in Latin America for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6.5. Radiopharmaceuticals Market in Latin America for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.6.6. Radiopharmaceuticals Market in Latin America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.7. Radiopharmaceuticals Market in Latin America: Distribution by End-user

27.7.1. Radiopharmaceuticals Market in Latin America for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.7.2. Radiopharmaceuticals Market in Latin America for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

27.7.3. Radiopharmaceuticals Market in Latin America for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 28. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

28.1 Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Radioisotope

28.1.1. Radiopharmaceuticals Market in Middle East and North Africa for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.1.2. Radiopharmaceuticals Market in Middle East and North Africa for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.1.3. Radiopharmaceuticals Market in Middle East and North Africa for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.1.4. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.2. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Emitter

28.2.1. Radiopharmaceuticals Market in Middle East and North Africa for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.2.2. Radiopharmaceuticals Market in Middle East and North Africa for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.2.3. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.3. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Purpose of Radiopharmaceutical

28.3.1. Radiopharmaceuticals Market in Middle East and North Africa for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.3.2. Radiopharmaceuticals Market in Middle East and North Africa for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.4. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Diagnostic Radiopharmaceutical

28.4.1. Radiopharmaceuticals Market in Middle East and North Africa for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.4.2. Radiopharmaceuticals Market in Middle East and North Africa for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.5. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Type of Production Method

28.5.1. Radiopharmaceuticals Market in Middle East and North Africa for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.5.2. Radiopharmaceuticals Market in Middle East and North Africa for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.5.3. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by Therapeutic Area

28.6.1. Radiopharmaceuticals Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6.2. Radiopharmaceuticals Market in Middle East and North Africa for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6.3. Radiopharmaceuticals Market in Middle East and North Africa for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6.4. Radiopharmaceuticals Market in Middle East and North Africa for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6.5. Radiopharmaceuticals Market in Middle East and North Africa for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.6.6. Radiopharmaceuticals Market in Middle East and North Africa for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.7. Radiopharmaceuticals Market in Middle East and North Africa: Distribution by End-user

28.7.1. Radiopharmaceuticals Market in Middle East and North Africa for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.7.2. Radiopharmaceuticals Market in Middle East and North Africa for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

28.7.3. Radiopharmaceuticals Market in Middle East and North Africa for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

+ 29. SUPPLY CHAIN ANALYSIS

29.1. Brief Overview of Processes and Stakeholders Involved

29.2. Schematic Representation of Radiopharmaceuticals Synthesis Process

29.3. Key Challenges and Mitigation Strategies

+ 30. CONCLUDING INSIGHTS
+ 31. EXECUTIVE INSIGHTS

31.1. Chapter Overview

31.2. Company A

31.2.1. Company Snapshot

31.2.2. Interview Transcript: Chief Executive Officer, Small Company

31.3. Company B

31.3.1. Company Snapshot

31.3.2. Interview Transcript: Chief Executive Officer, Very Small Company

31.4. Company C

31.4.1. Company Snapshot

31.4.2. Interview Transcript: Chief Executive Officer, Mid-Sized Company

31.5. Company D

31.5.1. Company Snapshot

31.5.2. Interview Transcript: Chief Executive Officer, Large Company

31.6. Company E

31.6.1. Company Snapshot

31.6.2. Interview Transcript: Chair, Department of Radiology, Large Organization

31.7. Company F

31.7.1. Company Snapshot

31.7.2. Interview Transcript: President, Mid-Sized Company

31.8. Company G

31.8.1. Company Snapshot

31.8.2. Interview Transcript: Vice President, Clinical Development, Large Organization

31.9. Company H

31.9.1. Company Snapshot

31.9.2. Interview Transcript: Medical Director, Mid-Sized Company

31.10. Company I

31.10.1. Company Snapshot

31.10.2. Interview Transcript: Radiation Oncologist and Co-director, Very Large Organization

31.11. Company J

31.11.1. Company Snapshot

31.11.2. Interview Transcript: Doctor of Medicine, Very Large Organization

+ 32. APPENDIX 1: TABULATED DATA
 
+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 3.3 Market Dynamics: Example List of Parameters

Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis

Figure 6.1 Mechanism of Action of Radiopharmaceuticals

Figure 6.2 Advantages of Radiopharmaceuticals

Figure 8.1 Approved Radiopharmaceutical Therapy Programs: Distribution by Format of Radiopharmaceutical

Figure 8.2 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope

Figure 8.3 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter

Figure 8.4 Approved Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical

Figure 8.5 Approved Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area

Figure 8.6 Approved Radiopharmaceutical Therapy Programs: Distribution by Target Indication

Figure 8.7 Approved Radiopharmaceutical Therapy Programs: Distribution by Route of Administration

Figure 8.8 Approved Radiopharmaceutical Therapy Programs: Distribution by Dosage Frequency

Figure 8.9 Approved Radiopharmaceutical Developers: Distribution by Year of Establishment and Location of Headquarters

Figure 8.10 Approved Radiopharmaceutical Developers: Distribution by Company Size and Year of Establishment

Figure 8.11 Approved Radiopharmaceutical Developers: Distribution by Location of Headquarters Company Size

Figure 8.12 Most Active Players: Distribution by Number of Approved Radiopharmaceuticals

Figure 9.1 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Stage of Development

Figure 9.2 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope

Figure 9.3 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter

Figure 9.4 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical

Figure 9.5 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Therapy

Figure 9.6 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Route of Administration

Figure 9.7 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Indication

Figure 9.8 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area

Figure 9.9 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Patient Population

Figure 9.10 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Year of Establishment and Location of Headquarters

Figure 9.11 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Company Size and Year of Establishment

Figure 9.12 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Location of Headquarters Company Size

Figure 9.13 Most Active Players: Distribution by Number of Clinical and Preclinical Radiopharmaceuticals

Figure 11.1 Partnerships and Collaborations: Analysis by Year of Partnership

Figure 11.2 Partnerships and Collaborations: Analysis by Type of Partnership

Figure 11.3 Partnerships and Collaborations: Analysis by Year and Type of Partnership

Figure 11.4 Partnerships and Collaborations: Analysis by Type of Radioisotope

Figure 11.5 Partnerships and Collaborations: Analysis by Type of Emission

Figure 11.6 Partnerships and Collaborations: Analysis by Type of Molecule

Figure 11.7 Partnerships and Collaborations: Analysis by Therapeutic Area

Figure 11.8 Partnerships and Collaborations: Analysis by Purpose of Radiopharmaceutical

Figure 11.9 Partnerships and Collaborations: Analysis by Type of Partner

Figure 11.10 Most Active Players: Analysis by Number of Partnerships

Figure 11.11 Partnerships and Collaborations: Analysis by Local and International Agreements

Figure 11.12 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements

Figure 12.1 Clinical Trial Analysis: Analysis by Trial Registration Year

Figure 12.2 Clinical Trial Analysis: Analysis by Analysis by Trial Status

Figure 12.3 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status

Figure 12.4 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year

Figure 12.5 Clinical Trial Analysis: Analysis by Trial Phase

Figure 12.6 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase

Figure 12.7 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator

Figure 12.8 Clinical Trial Analysis: Analysis by Study Design

Figure 12.9 Clinical Trial Analysis: Analysis by Patient Gender

Figure 12.10 Clinical Trial Analysis: Analysis by Target Patient Population

Figure 12.11 Most Active Industry Players: Analysis by Number of Clinical Trials

Figure 12.12 Most Active Non- Industry Players: Analysis by Number of Clinical Trials

Figure 12.13 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled

Figure 12.14 Clinical Trial Analysis: Analysis by Trial Status and Geography

Figure 12.15 Clinical Trial Analysis: Analysis of` Patients Enrolled by Trial Status and Geography

Figure 13.1 Megatrend Analysis: An Overview of Emerging Trends

Figure 15.1 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Scenario Analysis

Figure 15.2 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Conservative Scenario

Figure 15.3 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Optimistic Scenario

Figure 16.1 Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 16.2 Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 16.3 Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 16.4 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 17.1 Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 17.2 Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 17.3 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 18.1 Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 18.2 Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 19.1 Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 19.2 Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 20.1 Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 20.2 Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 20.3 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.1 Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.2 Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.3 Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.4 Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.5 Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.6 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.7 Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.8 Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 21.9 Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.1 Radiopharmaceuticals Market: Distribution by Geographical Regions

Figure 23.2 Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.3 Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.4 Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.5 Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.6 Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.7 Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.8 Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.9 Radiopharmaceuticals Market in the Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.10 Radiopharmaceuticals Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.11 Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.12 Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.13 Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.14 Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.15 Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.16 Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.17 Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.18 Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.19 Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.20 Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.21 Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.22 Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.23 Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.24 Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 23.25 Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Figure 24.1 Supply Chain Analysis: Brief Overview of Processes and Stakeholders Involved

+ List of Tables

Table 8.1 List of Approved Radiopharmaceutical Therapy Programs

Table 8.2 List of Approved Radiopharmaceutical Developers

Table 9.1 List of Clinical and Preclinical Radiopharmaceutical Therapy Programs

Table 9.2 List of Clinical and Preclinical Radiopharmaceutical Developers

Table 10.1 3B Pharmaceuticals: Company Overview

Table 10.2 3B Pharmaceuticals: Radiopharmaceuticals Pipeline

Table 10.3 3B Pharmaceuticals: Recent Initiatives

Table 10.4 Curium Pharma: Company Overview

Table 10.5 Curium Pharma: Radiopharmaceuticals Pipeline

Table 10.6 Curium Pharma: Recent Initiatives

Table 10.7 ITM Radiopharma: Company Overview

Table 10.8 ITM Radiopharma: Radiopharmaceuticals Pipeline

Table 10.9 ITM Radiopharma: Recent Initiatives

Table 10.10 Jubilant Radiopharma: Company Overview

Table 10.11 Jubilant Radiopharma: Radiopharmaceuticals Pipeline

Table 10.12 Jubilant Radiopharma: Recent Initiatives

Table 10.13 Lantheus: Company Overview

Table 10.14 Lantheus: Radiopharmaceuticals Pipeline

Table 10.15 Lantheus: Recent Initiatives

Table 10.16 Yantai LNC Biotechnology: Company Overview

Table 10.17 Yantai LNC Biotechnology: Radiopharmaceuticals Pipeline

Table 10.18 Yantai LNC Biotechnology: Recent Initiatives

Table 10.19 Norroy Biosciences: Company Overview

Table 10.20 Norroy Biosciences: Radiopharmaceuticals Pipeline

Table 10.21 Norroy Biosciences: Recent Initiatives

Table 10.22 Sinotau Pharmaceutical: Company Overview

Table 10.23 Sinotau Pharmaceutical: Radiopharmaceuticals Pipeline

Table 10.24 Sinotau Pharmaceutical: Recent Initiatives

Table 10.25 Telix Pharmaceuticals: Company Overview

Table 10.26 Telix Pharmaceuticals: Radiopharmaceuticals Pipeline

Table 10.27 Telix Pharmaceuticals: Recent Initiatives

Table 11.1 Radiopharmaceuticals: List of Partnerships and Collaborations, Since 2021

Table 11.2 Radiopharmaceuticals: List of Clinical Trials, Since 2021

Table 26.1 Approved Radiopharmaceutical Therapy Programs: Distribution by Format of Radiopharmaceutical

Table 26.2 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope

Table 26.3 Approved Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter

Table 26.4 Approved Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical

Table 26.5 Approved Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area

Table 26.6 Approved Radiopharmaceutical Therapy Programs: Distribution by Target Indication

Table 26.7 Approved Radiopharmaceutical Therapy Programs: Distribution by Route of Administration

Table 26.8 Approved Radiopharmaceutical Therapy Programs: Distribution by Dosage Frequency

Table 26.9 Approved Radiopharmaceutical Developers: Distribution by Year of Establishment

Table 26.10 Approved Radiopharmaceutical Developers: Distribution by Company Size

Table 26.11 Approved Radiopharmaceutical Developers: Distribution by Location of Headquarters

Table 26.12 Most Active Players: Distribution by Number of Approved Radiopharmaceuticals

Table 26.13 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Stage of Development

Table 26.14 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Radioisotope

Table 26.15 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Emitter

Table 26.16 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Purpose of Radiopharmaceutical

Table 26.17 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Type of Therapy

Table 26.18 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Route of Administration

Table 26.19 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Indication

Table 26.20 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Therapeutic Area

Table 26.21 Clinical and Preclinical Radiopharmaceutical Therapy Programs: Distribution by Target Patient Population

Table 26.22 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Year of Establishment

Table 26.23 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Company Size

Table 26.24 Clinical and Preclinical Radiopharmaceutical Developers: Distribution by Location of Headquarters

Table 26.25 Most Active Players: Distribution by Number of Clinical and Preclinical Radiopharmaceuticals

Table 26.26 Partnerships and Collaborations: Analysis by Year of Partnership

Table 26.27 Partnerships and Collaborations: Analysis by Type of Partnership

Table 26.28 Partnerships and Collaborations: Analysis by Year and Type of Partnership

Table 26.29 Partnerships and Collaborations: Analysis by Type of Radioisotope

Table 26.30 Partnerships and Collaborations: Analysis by Type of Emission

Table 26.31 Partnerships and Collaborations: Analysis by Type of Molecule

Table 26.32 Partnerships and Collaborations: Analysis by Therapeutic Area

Table 26.33 Partnerships and Collaborations: Analysis by Purpose of Radiopharmaceutical

Table 26.34 Partnerships and Collaborations: Analysis by Type of Partner

Table 26.35 Most Active Players: Analysis by Number of Partnerships

Table 26.36 Partnerships and Collaborations: Analysis by Local and International Agreements

Table 26.37 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements

Table 26.38 Clinical Trial Analysis: Analysis by Trial Registration Year

Table 26.39 Clinical Trial Analysis: Analysis by Analysis by Trial Status

Table 26.40 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status

Table 26.41 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year

Table 26.42 Clinical Trial Analysis: Analysis by Trial Phase

Table 26.43 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase

Table 26.44 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator

Table 26.45 Clinical Trial Analysis: Analysis by Study Design

Table 26.46 Clinical Trial Analysis: Analysis by Patient Gender

Table 26.47 Clinical Trial Analysis: Analysis by Target Patient Population

Table 26.48 Most Active Industry Players: Analysis by Number of Clinical Trials

Table 26.49 Most Active Non- Industry Players: Analysis by Number of Clinical Trials

Table 26.50 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled

Table 26.51 Clinical Trial Analysis: Analysis by Trial Status and Geography

Table 26.52 Clinical Trial Analysis: Analysis of` Patients Enrolled by Trial Status and Geography

Table 26.53 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Scenario Analysis

Table 26.54 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Conservative Scenario

Table 26.55 Global Radiopharmaceuticals Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040), Optimistic Scenario

Table 26.56 Global Radiopharmaceuticals Market, Analysis by Type of Radioisotope

Table 26.57 Radiopharmaceuticals Market for Technetium-99m, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.58 Radiopharmaceuticals Market for Leutetium-177, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.59 Radiopharmaceuticals Market for Fluorine-18, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.60 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.61 Global Radiopharmaceuticals Market, Analysis by Type of Emitter

Table 26.62 Radiopharmaceuticals Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.63 Radiopharmaceuticals Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.64 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.65 Global Radiopharmaceuticals Market, Analysis by Purpose of Radiopharmaceuticals

Table 26.66 Radiopharmaceuticals Market for Diagnostics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.67 Radiopharmaceuticals Market for Therapeutics, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.68 Global Radiopharmaceuticals Market, Analysis by Type of Diagnostic Radiopharmaceutical

Table 26.69 Radiopharmaceuticals Market for PET Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.70 Radiopharmaceuticals Market for SPECT Imaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.71 Global Radiopharmaceuticals Market, Analysis by Type of Production Method

Table 26.72 Radiopharmaceuticals Market for Nuclear Reactors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.73 Radiopharmaceuticals Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.74 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.75 Global Radiopharmaceuticals Market, Analysis by Therapeutic Area

Table 26.76 Radiopharmaceuticals Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.77 Radiopharmaceuticals Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.78 Radiopharmaceuticals Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.79 Radiopharmaceuticals Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.80 Radiopharmaceuticals Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.81 Radiopharmaceuticals Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.82 Global Radiopharmaceuticals Market, Analysis by End User

Table 26.83 Radiopharmaceuticals Market for Hospitals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.84 Radiopharmaceuticals Market for Diagnostic Centers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.85 Radiopharmaceuticals Market for Research Institutes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.86 Global Radiopharmaceuticals Market, Analysis by Geographical Regions

Table 26.87 Radiopharmaceuticals Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.88 Radiopharmaceuticals Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.89 Radiopharmaceuticals Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.90 Radiopharmaceuticals Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.91 Radiopharmaceuticals Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.92 Radiopharmaceuticals Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.93 Radiopharmaceuticals Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.94 Radiopharmaceuticals Market in the Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.95 Radiopharmaceuticals Market in UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.96 Radiopharmaceuticals Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.97 Radiopharmaceuticals Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.98 Radiopharmaceuticals Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.99 Radiopharmaceuticals Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.100 Radiopharmaceuticals Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.101 Radiopharmaceuticals Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.102 Radiopharmaceuticals Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.103 Radiopharmaceuticals Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.104 Radiopharmaceuticals Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.105 Radiopharmaceuticals Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.106 Radiopharmaceuticals Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.107 Radiopharmaceuticals Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.108 Radiopharmaceuticals Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.109 Radiopharmaceuticals Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

Table 26.110 Radiopharmaceuticals Market in Rest of Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)